Organization (Industry)
MetaVia Inc.
ClinicalTrials.gov lists MetaVia Inc. as lead sponsor of 15 trials. It has 7 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers MetaVia Inc.: 15 lead-sponsored trials and 2 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (13)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dyslipidemias | 9 |
| Hyperlipidemias | 9 |
| Hypercholesterolemia | 8 |
| Fatty Liver | 2 |
| Hypertriglyceridemia | 2 |
Showing 5 of 13 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 1 |
| 2020 | 2 |
| 2018 | 1 |
| 2016 | 3 |
| 2013 | 1 |
| 2003 | 1 |
| 2002 | 1 |
| 2001 | 1 |
| 2000 | 2 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (7)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials | Ownership basis |
|---|---|---|---|---|
| Niclosamide | COVID-19 | Phase 2/3 | 1 | Inferred lead |
| Niclosamide | Respiratory Distress Syndrome | Phase 2/3 | 1 | Inferred lead |
| DA-1241 | Fatty Liver | Phase 2 | 1 | Inferred lead |
| DA-1241 | Non-alcoholic Fatty Liver Disease | Phase 2 | 1 | Inferred lead |
| SITAGLIPTIN | Fatty Liver | Phase 2 | 1 | Generic, not holder |
Showing 5 of 7 active programs.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials | Ownership basis |
|---|---|---|
| Niclosamide | 2 | Inferred lead |
| ATORVASTATIN | 2 | Generic, not holder |
| SITAGLIPTIN | 1 | Generic, not holder |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 3 hit target (n=3) | 0 of 3 on time (n=3) |
Journals published in (2)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The American journal of cardiology | 2 |
| Journal of clinical lipidology | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 9 | 1 | 2025-12-23 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts; non-USD filers converted to USD at the annual average rate.
| Fiscal year | Revenue | Net income | R&D |
|---|---|---|---|
| 2025 | not reported | -$13.0M | $6.80M |
| 2024 | not reported | -$27.6M | $21.6M |
| 2023 | not reported | -$12.5M | $9.16M |
| 2022 | not reported | -$14.0M | $2.78M |
| 2021 | not reported | -$15.3M | $6.55M |
| 2020 | not reported | -$29.7M | $4.53M |
| 2019 | not reported | -$21.3M | $5.32M |
| 2018 | not reported | -$15.5M | $5.07M |
| 2017 | not reported | -$33.4M | $22.7M |
| 2016 | not reported | -$14.6M | $8.74M |
Showing 10 of 11 fiscal years.
Financing and grant events (44)
Shown in this order: most recent first; amounts in US dollars.
| Date | Round type | Amount | Source |
|---|---|---|---|
| 2026-07-02 | Other financing | not disclosed | EDGAR offerings |
| 2026-07-02 | ATM offering | not disclosed | SEC extracted |
| 2026-04-07 | Other financing | not disclosed | EDGAR offerings |
| 2026-01-16 | Other financing | not disclosed | EDGAR offerings |
| 2026-01-16 | Public offering | $7.70M | SEC extracted |
Showing 5 of 44 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Dong-A ST (South Korea) | Co sponsors trial with | 1 |
| Emory University | Co sponsors trial with | 1 |
Latest dated events (69)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-02 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-07-02 | At-the-market offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-04-07 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-01-16 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-01-16 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 69 events.
Biomarker capability evidence (76)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CP | Trial collaborator | Named in trial inclusion criteria |
| HMGCR | Trial sponsor | Named in trial inclusion criteria |
| PCSK9 | Trial sponsor | Named in trial inclusion criteria |
| SLC5A2 | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 76 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.